Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EPS (Weighted Average and Diluted) (2018 - 2025)

Tandem Diabetes Care (TNDM) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$0.29 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 17.14% year-over-year to -$0.29, compared with a TTM value of -$3.04 through Dec 2025, down 108.22%, and an annual FY2025 reading of -$3.04, down 106.8% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.29 for Q3 2025 at Tandem Diabetes Care, up from -$0.78 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.17 in Q4 2021 and bottomed at -$1.97 in Q1 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.48, with a median of -$0.35 recorded in 2024.
  • The sharpest move saw EPS (Weighted Average and Diluted) surged 160.0% in 2021, then tumbled 944.44% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.17 in 2021, then tumbled by 247.06% to -$0.25 in 2022, then crashed by 84.0% to -$0.46 in 2023, then skyrocketed by 102.17% to $0.01 in 2024, then plummeted by 3000.0% to -$0.29 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for TNDM at -$0.29 in Q3 2025, -$0.78 in Q2 2025, and -$1.97 in Q1 2025.